n/a
Article Publish Status: FREE
Abstract Title:

Cordycepin inhibits the proliferation and progression of NPC by targeting the MAPK/ERK andβ-catenin pathways.

Abstract Source:

Oncol Lett. 2022 Jan ;23(1):20. Epub 2021 Nov 16. PMID: 34858524

Abstract Author(s):

Yaqi Zhou, Xueshuang Mei, Ying Li, Weiqiang Yang, Xi Su, Hongyi Hu

Article Affiliation:

Yaqi Zhou

Abstract:

Cordycepin is an extract from thegenus of ascomycete fungi. In the present study, the anticancer potential of cordycepin against nasopharyngeal carcinoma (NPC), and the potential underlying mechanisms, were investigated. Using Cell Counting Kit 8, wound-healing and Transwell assays, cordycepin was found to reduce the viability and inhibit the migration of C666-1 cells in a dose-dependent manner. In addition, in colony formation assays, co-treatment with cordycepin and cisplatin inhibited the proliferation of C666-1 cells. Furthermore, RNA sequencing analysis identified 72 significantly differentially expressed genes and different signaling pathways that may be regulated by cordycepin. After treatment with cordycepin, the expression levels of ERK1/2, phosphorylated ERK1/2 andβ-catenin were significantly downregulated. Therefore, cordycepin may be a novel candidate for NPC treatment or a co-treatment candidate with cisplatin in chemotherapy.

Study Type : In Vitro Study

Print Options


Key Research Topics

This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.